Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012205 | 0.86 | SIGMAR1 (0.42) | SIGMAR1L3MBTL1ALDH1A1CYP2A6KMT2A | |
| SCHEMBL5010705 | 0.85 | HTR1B (0.46) | SIGMAR1ALDH1A1CYP2A6KMT2ALMNA | |
| SCHEMBL7411647 | 0.84 | SIGMAR1 (0.49) | SIGMAR1L3MBTL1ALDH1A1CYP2A6KMT2A | |
| SCHEMBL5010596 | 0.83 | HTR1B (0.41) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL5009727 | 0.82 | HTR1B (0.40) | SIGMAR1L3MBTL1ALDH1A1KMT2AKDM4E | |
| SCHEMBL1573639 | 0.78 | ALDH1A1 (0.41) | SIGMAR1ALDH1A1CYP2A6KMT2AKDM4E | |
| SCHEMBL1486294 | 0.76 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CYP2A6TSHRKDM4E | |
| SCHEMBL29657743 | 0.75 | SIGMAR1 (0.54) | SIGMAR1L3MBTL1ALDH1A1CYP2A6KMT2A | |
| SCHEMBL14461587 | 0.75 | SIGMAR1 (0.54) | SIGMAR1L3MBTL1ALDH1A1CYP2A6KMT2A | |
| SCHEMBL517207 | 0.75 | SIGMAR1 (0.54) | SIGMAR1L3MBTL1ALDH1A1CYP2A6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| EP-2088151-A1 | GOLD COMPLEX, METHOD FOR PRODUCTION OF THE GOLD COMPLEX, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT ELEMENT USING THE GOLD COMPLEX | Ube Industries, Ltd. (JP) | 2009-08-12 | — | — | EP | claimed |
| EP-1814860-B1 | SUBSTITUTED 5-CARBOXYAMIDE PYRAZOLES AND [1,2,4]TRIAZOLES AS ANTIVIRAL AGENTS | SCHERING CORP (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2011099832-A2 | NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CRYSTALGENOMICS, INC. (KR) | 2011-08-18 | — | — | WO | disclosed |
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-2088151-A1 | GOLD COMPLEX, METHOD FOR PRODUCTION OF THE GOLD COMPLEX, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT ELEMENT USING THE GOLD COMPLEX | Ube Industries, Ltd. (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-0781310-B1 | MONO-N-ALKYL-QUINACRIDONE PIGMENTS | CIBA GEIGY AG (CH) | 1998-10-21 | — | — | EP | disclosed |
| US-5725651-A | Mono-N-alkyl-quinacridone pigments | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-03-10 | — | — | US | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0781310-A1 | MONO-N-ALKYL-QUINACRIDONE PIGMENTS | Ciba SC Holding AG (CH) | 1997-07-02 | — | — | EP | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| WO-1996008536-A1 | MONO-N-ALKYL-QUINACRIDONE PIGMENTS | CIBA SPECIALTY CHEMICAL HOLDING INC. (CH) | 1996-03-21 | — | — | WO | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | APOL1, UFL1, ACSL3 | SIGMAR1 3437/4885L3MBTL1 2111/4885ALDH1A1 435/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | SIGMAR1 1156/4885L3MBTL1 2102/4885ALDH1A1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.